Antibiotic resistance of Campylobacter species in a pediatric cohort study

Francesca Schiaffino, Josh M. Colston, Maribel Paredes-Olortegui, Ruthly Francois, Nora Pisanic, Rosa Burga, Pablo Penataro Yori, Margaret Kosek

Research output: Contribution to journalArticle

Abstract

The objective of this study was to determine the phenotypic patterns of antibiotic resistance and the epidemiology of drug-resistant Campylobacter spp. from a low-resource setting. A birth cohort of 303 patients was followed until 5 years of age. Stool samples from asymptomatic children (n 10,008) and those with diarrhea (n 3,175) were cultured for Campylobacter. Disk diffusion for ciprofloxacin (CIP), nalidixic acid (NAL), erythromycin (ERY), azithromycin (AZM), tetracycline (TE), gentamicin (GM), ampicillin (AMP), amoxicillin and clavulanic acid (AMC), ceftriaxone (CRO), chloramphenicol (C), and trimethoprim-sulfamethoxazole (TMS) was determined. Antibiotic resistances in Campylobacter jejuni and non-C. jejuni isolates from surveillance and diarrhea samples were compared, and the association between personal macrolide exposure and subsequent occurrence of a macrolide-resistant Campylobacter spp. was assessed. Of 917 Campylobacter isolates, 77.4% of C. jejuni isolates and 79.8% of non-C. jejuni isolates were resistant to ciprofloxacin, while 4.9% of C. jejuni isolates and 24.8% of non-C. jejuni isolates were not susceptible to azithromycin. Of the 303 children, 33.1% had been diagnosed with a Campylobacter strain nonsusceptible to both azithromycin and ciprofloxacin. Personal macrolide exposure did not affect the risk of macrolide-resistant Campylobacter. Amoxicillin and clavulanic acid (94.0%) was one of the antibiotics with the highest rates of susceptibility. There is a high incidence of quinolone- and macrolide-resistant Campylobacter infections in infants under 24 months of age. Given the lack of association between personal exposure to macrolides and a subsequent Campylobacter infection resistant to macrolides, there is a need to evaluate the source of multidrug-resistant (MDR) Campylobacter. This study provides compelling evidence to propose amoxicillin/clavulanic acid as a treatment for campylobacteriosis.

Original languageEnglish (US)
Article numbere01911-18
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Campylobacter
Macrolides
Microbial Drug Resistance
Cohort Studies
Pediatrics
Amoxicillin-Potassium Clavulanate Combination
Azithromycin
Campylobacter jejuni
Ciprofloxacin
Campylobacter Infections
Diarrhea
Nalidixic Acid
Ceftriaxone
Quinolones
Sulfamethoxazole Drug Combination Trimethoprim
Chloramphenicol
Erythromycin
Ampicillin
Gentamicins
Tetracycline

Keywords

  • Antibiotic resistance
  • Campylobacter
  • Diarrhea
  • Iquitos
  • MAL-ED

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Antibiotic resistance of Campylobacter species in a pediatric cohort study. / Schiaffino, Francesca; Colston, Josh M.; Paredes-Olortegui, Maribel; Francois, Ruthly; Pisanic, Nora; Burga, Rosa; Penataro Yori, Pablo; Kosek, Margaret.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 2, e01911-18, 01.02.2019.

Research output: Contribution to journalArticle

Schiaffino, F, Colston, JM, Paredes-Olortegui, M, Francois, R, Pisanic, N, Burga, R, Penataro Yori, P & Kosek, M 2019, 'Antibiotic resistance of Campylobacter species in a pediatric cohort study', Antimicrobial Agents and Chemotherapy, vol. 63, no. 2, e01911-18. https://doi.org/10.1128/AAC.01911-18
Schiaffino F, Colston JM, Paredes-Olortegui M, Francois R, Pisanic N, Burga R et al. Antibiotic resistance of Campylobacter species in a pediatric cohort study. Antimicrobial Agents and Chemotherapy. 2019 Feb 1;63(2). e01911-18. https://doi.org/10.1128/AAC.01911-18
Schiaffino, Francesca ; Colston, Josh M. ; Paredes-Olortegui, Maribel ; Francois, Ruthly ; Pisanic, Nora ; Burga, Rosa ; Penataro Yori, Pablo ; Kosek, Margaret. / Antibiotic resistance of Campylobacter species in a pediatric cohort study. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 2.
@article{796bbfcb71b84462a09029aba911b587,
title = "Antibiotic resistance of Campylobacter species in a pediatric cohort study",
abstract = "The objective of this study was to determine the phenotypic patterns of antibiotic resistance and the epidemiology of drug-resistant Campylobacter spp. from a low-resource setting. A birth cohort of 303 patients was followed until 5 years of age. Stool samples from asymptomatic children (n 10,008) and those with diarrhea (n 3,175) were cultured for Campylobacter. Disk diffusion for ciprofloxacin (CIP), nalidixic acid (NAL), erythromycin (ERY), azithromycin (AZM), tetracycline (TE), gentamicin (GM), ampicillin (AMP), amoxicillin and clavulanic acid (AMC), ceftriaxone (CRO), chloramphenicol (C), and trimethoprim-sulfamethoxazole (TMS) was determined. Antibiotic resistances in Campylobacter jejuni and non-C. jejuni isolates from surveillance and diarrhea samples were compared, and the association between personal macrolide exposure and subsequent occurrence of a macrolide-resistant Campylobacter spp. was assessed. Of 917 Campylobacter isolates, 77.4{\%} of C. jejuni isolates and 79.8{\%} of non-C. jejuni isolates were resistant to ciprofloxacin, while 4.9{\%} of C. jejuni isolates and 24.8{\%} of non-C. jejuni isolates were not susceptible to azithromycin. Of the 303 children, 33.1{\%} had been diagnosed with a Campylobacter strain nonsusceptible to both azithromycin and ciprofloxacin. Personal macrolide exposure did not affect the risk of macrolide-resistant Campylobacter. Amoxicillin and clavulanic acid (94.0{\%}) was one of the antibiotics with the highest rates of susceptibility. There is a high incidence of quinolone- and macrolide-resistant Campylobacter infections in infants under 24 months of age. Given the lack of association between personal exposure to macrolides and a subsequent Campylobacter infection resistant to macrolides, there is a need to evaluate the source of multidrug-resistant (MDR) Campylobacter. This study provides compelling evidence to propose amoxicillin/clavulanic acid as a treatment for campylobacteriosis.",
keywords = "Antibiotic resistance, Campylobacter, Diarrhea, Iquitos, MAL-ED",
author = "Francesca Schiaffino and Colston, {Josh M.} and Maribel Paredes-Olortegui and Ruthly Francois and Nora Pisanic and Rosa Burga and {Penataro Yori}, Pablo and Margaret Kosek",
year = "2019",
month = "2",
day = "1",
doi = "10.1128/AAC.01911-18",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Antibiotic resistance of Campylobacter species in a pediatric cohort study

AU - Schiaffino, Francesca

AU - Colston, Josh M.

AU - Paredes-Olortegui, Maribel

AU - Francois, Ruthly

AU - Pisanic, Nora

AU - Burga, Rosa

AU - Penataro Yori, Pablo

AU - Kosek, Margaret

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The objective of this study was to determine the phenotypic patterns of antibiotic resistance and the epidemiology of drug-resistant Campylobacter spp. from a low-resource setting. A birth cohort of 303 patients was followed until 5 years of age. Stool samples from asymptomatic children (n 10,008) and those with diarrhea (n 3,175) were cultured for Campylobacter. Disk diffusion for ciprofloxacin (CIP), nalidixic acid (NAL), erythromycin (ERY), azithromycin (AZM), tetracycline (TE), gentamicin (GM), ampicillin (AMP), amoxicillin and clavulanic acid (AMC), ceftriaxone (CRO), chloramphenicol (C), and trimethoprim-sulfamethoxazole (TMS) was determined. Antibiotic resistances in Campylobacter jejuni and non-C. jejuni isolates from surveillance and diarrhea samples were compared, and the association between personal macrolide exposure and subsequent occurrence of a macrolide-resistant Campylobacter spp. was assessed. Of 917 Campylobacter isolates, 77.4% of C. jejuni isolates and 79.8% of non-C. jejuni isolates were resistant to ciprofloxacin, while 4.9% of C. jejuni isolates and 24.8% of non-C. jejuni isolates were not susceptible to azithromycin. Of the 303 children, 33.1% had been diagnosed with a Campylobacter strain nonsusceptible to both azithromycin and ciprofloxacin. Personal macrolide exposure did not affect the risk of macrolide-resistant Campylobacter. Amoxicillin and clavulanic acid (94.0%) was one of the antibiotics with the highest rates of susceptibility. There is a high incidence of quinolone- and macrolide-resistant Campylobacter infections in infants under 24 months of age. Given the lack of association between personal exposure to macrolides and a subsequent Campylobacter infection resistant to macrolides, there is a need to evaluate the source of multidrug-resistant (MDR) Campylobacter. This study provides compelling evidence to propose amoxicillin/clavulanic acid as a treatment for campylobacteriosis.

AB - The objective of this study was to determine the phenotypic patterns of antibiotic resistance and the epidemiology of drug-resistant Campylobacter spp. from a low-resource setting. A birth cohort of 303 patients was followed until 5 years of age. Stool samples from asymptomatic children (n 10,008) and those with diarrhea (n 3,175) were cultured for Campylobacter. Disk diffusion for ciprofloxacin (CIP), nalidixic acid (NAL), erythromycin (ERY), azithromycin (AZM), tetracycline (TE), gentamicin (GM), ampicillin (AMP), amoxicillin and clavulanic acid (AMC), ceftriaxone (CRO), chloramphenicol (C), and trimethoprim-sulfamethoxazole (TMS) was determined. Antibiotic resistances in Campylobacter jejuni and non-C. jejuni isolates from surveillance and diarrhea samples were compared, and the association between personal macrolide exposure and subsequent occurrence of a macrolide-resistant Campylobacter spp. was assessed. Of 917 Campylobacter isolates, 77.4% of C. jejuni isolates and 79.8% of non-C. jejuni isolates were resistant to ciprofloxacin, while 4.9% of C. jejuni isolates and 24.8% of non-C. jejuni isolates were not susceptible to azithromycin. Of the 303 children, 33.1% had been diagnosed with a Campylobacter strain nonsusceptible to both azithromycin and ciprofloxacin. Personal macrolide exposure did not affect the risk of macrolide-resistant Campylobacter. Amoxicillin and clavulanic acid (94.0%) was one of the antibiotics with the highest rates of susceptibility. There is a high incidence of quinolone- and macrolide-resistant Campylobacter infections in infants under 24 months of age. Given the lack of association between personal exposure to macrolides and a subsequent Campylobacter infection resistant to macrolides, there is a need to evaluate the source of multidrug-resistant (MDR) Campylobacter. This study provides compelling evidence to propose amoxicillin/clavulanic acid as a treatment for campylobacteriosis.

KW - Antibiotic resistance

KW - Campylobacter

KW - Diarrhea

KW - Iquitos

KW - MAL-ED

UR - http://www.scopus.com/inward/record.url?scp=85060794284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060794284&partnerID=8YFLogxK

U2 - 10.1128/AAC.01911-18

DO - 10.1128/AAC.01911-18

M3 - Article

C2 - 30420482

AN - SCOPUS:85060794284

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

M1 - e01911-18

ER -